Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites

ABSTRACT: Red blood cells (RBCs) infected with ring stage P. falciparum parasites (3D7 strain) at 10% parasitaemia and 2% haematocrit were treated with OZ277 (1 uM), OZ439 (1 uM), DHA (300 nM) or vehicle (0.03% DMSO). This was a 5-timepoint study, with samples taken 0, 1.5, 3, 6 and 9 h after drug or vehicle addition. Samples treated with vehicle acted as the untreated control. Samples from drug treated uninfected RBCs were also taken to ensure the observed drug effects were parasite specific.

ORGANISM(S): Human Homo Sapiens Plasmodium Falciparum Plasmodium Falciparum;homo Sapiens

TISSUE(S): Cultured Cells

DISEASE(S): Malaria

SUBMITTER: Carlo Giannangelo

PROVIDER: ST001202 | MetabolomicsWorkbench | Mon Jun 24 00:00:00 BST 2019

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites

Project description:Red blood cells (RBCs) infected with trophozoite stage P. falciparum parasites (3D7 strain) at 10% parasitaemia and 2% haematocrit were treated with OZ277 (300 nM), OZ439 (300 nM), DHA (100 nM) or vehicle (0.03% DMSO). This was a 4-timepoint study, with samples taken 0, 0.5, 1.5 and 3 h after drug or vehicle addition. Samples treated with vehicle acted as the untreated control. Samples from drug treated uninfected RBCs were also taken to ensure the observed drug effects were parasite specific.

2019-06-19 | ST001201 | MetabolomicsWorkbench

Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites

Project description:Red blood cells (RBCs) infected with trophozoite stage P. falciparum parasites (3D7 strain) at 10% parasitaemia and 2% haematocrit were treated with OZ277 (300 nM), OZ439 (300 nM), DHA (100 nM) or vehicle (0.03% DMSO). This was a 4-timepoint study, with samples taken 0, 3, 6 and 9 h after drug or vehicle addition. Samples treated with vehicle acted as the untreated control. Samples from drug treated uninfected RBCs were also taken to ensure the observed drug effects were parasite specific.

2019-06-25 | ST001204 | MetabolomicsWorkbench

Concomitant targeting of viral and host methyltransferases is essential for attenuating SARS-CoV-2

Project description:LC-MS/MS based investigation of protein abundance changes, induced by DZNep treatment in A549-ACE2 cell line (0.75 uM DZNep, vehicle PBS; 6h pre-treatment, harvested 24 h.p.i. with mock/SARS-CoV/SARS-CoV-2 at MOI 3) or primary human bronchial epithelial cells (NHBEs) (1.5 uM DZNep, vehicle PBS; 6h pre-treatment, harvested 36 h.p.i. with mock/SARS-CoV/SARS-CoV-2 at MOI 3), or by Tubercidin in A549-ACE2 cell line (1 uM Tubercidin, vehicle DMSO; 3h pre-treatment, harvested 24 h.p.i. with mock/SARS-CoV at MOI 0.01/SARS-CoV-2 at MOI 0.1).

2022-06-28 | PXD034361 | Pride

Toxicoproteomics of environmental mixtures in prostate diseases

Project description:These data are from the following 2 experiments: 1. normal prostate stromal cells (BHPRS1) treated with either 0.1 uM mono(2-ethylhexyl) phthalate (MEHP), 3 uM perfluorooctanesulfonic acid (PFOS), the mixture of MEHP+PFOS, or DMSO vehicle (0.06% v/v); n=3 each 2. metastatic prostate epithelial cells (MT10) treated with 50 uM mono(2-ethylhexyl) phthalate (MEHP) or DMSO vehicle (0.06% v/v); n=4 each

2024-05-21 | PXD014428 | Pride

Ribosome profiling of GC7/vehicle-treated mouse primary B cells

Project description:Mouse primary B cells were treated with 10 uM GC7 or vehicle control and processed for ribosome profiling. During harvesting, samples were spiked with S. cerevisiae lysate containing stable polysomes.

2019-07-09 | GSE133934 | GEO

Expression in lymphoblastoid cell lines following hydrogen peroxide bolus at 5 times

Project description:The general expression profile in human lymphoblastoid cell lines treated with 9 uM, 90 uM or 900 uM bolus of hydrogen peroxide at 0, 4,12,24, and 48 hours. Four cell lines (GM07055, GM14569, GM14467, and 12057) were treated separately and total RNA was pooled in equal amounts prior to labeling and hybridization to Affymetrix Human Gene 1.0 ST microarray.

2010-06-30 | GSE21800 | GEO

Effect of PNB-028 on Global gene expression in MAC-16 xenograft

Project description:Microarray studies were conducted with RNA isolated from vehicle- or PNB-028- treated MAC-16 colon cancer xenograft tumors (n=3/group). PNB-028 significantly regulated over 1400 genes compared to vehicle-treated samples with approximately 450 genes up-regulated and 1100 genes down-regulated by 1.5 fold or greater.

2015-08-17 | GSE72109 | GEO

Metal and Gene Expression

Project description:Human bronchial epithelial cells were treated with vehicle (control), VOSO4 (V, 50 uM) or ZnSO4 (Zn, 50 uM) for 4 hours. Keywords: other

2005-02-28 | GSE2111 | GEO

Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites

Project description:Red blood cells (RBCs) infected with trophozoite stage P. falciparum parasites (Cam3.IIR539T or Cam3.IIrev lines) at 4% parasitaemia and 2% haematocrit were treated with 100 nM of DHA, OZ277 or OZ439 for a duration of 1, 3 and 5 h, respectively. The K13-mutant artemisinin resistant parasite line used was Cam3.IIR539T. The K13-wildtype artemisinin sensitive parasite line used was Cam3.IIrev. The Samples treated with vehicle (DMSO) acted as the untreated control.

2019-06-26 | ST001205 | MetabolomicsWorkbench

Effect of Tubastatin A (HDAC6 specific inhibitor) on gene expression during differentiation of induced regulatory T cells (iTreg cells)

Project description:To investigate that Tubastain A, a HDAC6 inhibitor, has effect on early stage of iTreg differentiation, we treated naïve CD4+ T cells with DMSO (vehicle control) or 10 uM Tubastatin A and cultured the cells under Treg-skewing condition for 1 day. We then performed gene expression profiling analysis using data from RNA-seq of 2 different samples.

2022-08-12 | GSE210794 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data